Skip to main content

Table 2 Current State of Ototoxicity Monitoring

From: Insight into the current practice of ototoxicity monitoring during cisplatin therapy

   All Malignancies  
All malignancies
(n = 379)
Head and Neck
(n = 122)
Non-Head and Neck (n = 257)  
N (%) N (%) N (%) P value*
Prior to treatment with cisplatin
 Counselled about ototoxicity risk 196 (51.7) 103 (84.4) 93 (36.2) P < .0001
 Baseline pre-treatment audiogram ordered 92 (24.3) 70 (57.4) 22 (8.5) P < .0001
During cisplatin treatment
 Otologic Complaints 91 (24) 51 (41.8) 43 (16.7) P < .0001
  Treatment changed following otologic complaints 25 (27.5) 15 (29.4) 10 (23.2) P = .5010
 Audiogram ordered during treatment 17 (4.5) 6 (5.0) 11 (4.3) **P = .7937
Following cisplatin treatment
 Otologic Complaints (total) 130 (34.2) 75 (61.5) 55 (40) P < .0001
 1-month post-treatment audiogram 20 (7.8) 13 (10.6) 7 (2.7) **P = .0024
 3-month post-treatment audiogram 13 (5.1) 11 (9.0) 2 (0.8) **P = .0001
 6-month post-treatment audiogram 16 (6.2) 12 (9.8) 4 (1.6) **P = .0004
 Audiogram or Otolaryngology Consult 6–24 months post treatment 38 (15) 22 (18) 16 (6.2) P = .0003
  1. *P value used to compare Head and Neck Cancer and Non-Head and Neck Cancer Groups. Significance level set at p < .01, and results are bolded if statistically significant
  2. **Fisher exact test statistic value